treatment of myasthenia gravis research hub
4 indexed studies · 4 currently recruiting
- recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, randomized, single-dose, two-treatment, two-period, cross-over pilot bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
This study compares a new pyridostigmine medicine from Greece with an existing one from Germany. It's for healthy volunteers to see if the new medicine works the same way in the body. Pyridostigmine treats a muscle-weakening condition called myasthenia gravis.
Czechia - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fed conditions.
This study is comparing two versions of a drug called pyridostigmine bromide, used for myasthenia gravis, in healthy volunteers. Researchers want to see if a new version works in the body similarly to an existing one after participants have eaten.
Czechia - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
This study compares two versions of medicine (Pyridostigmine Bromide and Mestinon) used for a condition called myasthenia gravis. We want to see if they work the same way in healthy people. This helps make sure new medicines are just as good as existing ones.
Czechia - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
This study compares two versions of a medication for myasthenia gravis to see if they work the same way in healthy adults. It looks at how well a new tablet matches an existing one in the body.
Czechia